Avacta: Avacta (AVCT:LN) develops next-generation biologics using its proprietary Affimer® platform technology. This technology is based on a naturally occurring human protein, engineered to behave like an antibody, but smaller, simpler, more robust, easy to format, cheaper and quicker to produce, highly specific to the target and non-immunogenic. In February 2019, Moderna exercised option on taking Affimer candidate(s) into clinical development.

-Lead assets are PD-L1/LAG-3 single molecule bispecific inhibitor and a PD-L1 tumour microenvironment targeted innate immune activators (I-DASH inhibitors, STING agonists)
-First-in-man clinical data expected in 2020.
-Partnerships with Moderna and OncoSec (Gene delivery), Memorial Sloan Kettering (CAR-T), Iksuda and Tufts University Medical School (Drug conjugates)
-Affimer reagents business for diagnostics and research

Near term newsflow:
-Candidate selection for anti-PD-L1/LAG-3 bispecific Affimer clinical proprietary development – (June 2019)
-Remains on track to submit an IND/CTA application by the end of 2020
-Completion of IND enabling studies for anti-PD-L1/LAG-3 bispecific - 2020
-Affimer therapeutics and reagents/diagnostics licensing
Healthcare/Medical Devices & Instruments
Clinical Stage
Pre-Clinical Stage
Disease Space
Europe, Public
Market Cap
Therapeutic Modalities
Platform Technology
Unit 20, Ash Way
Thorp Arch Estate
Wetherby, York LS23 7FA
United Kingdom

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.